A growing number of US patients have initiated legal actions against manufacturers of GLP-1 drugs Ozempic and Mounjaro, alleging that the medications caused sudden vision loss. The lawsuits, filed against Novo Nordisk and Eli Lilly, center on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare condition linked to reduced blood flow to the optic nerve and permanent vision impairment. Patients claim the drugmakers failed to adequately warn them of the risks, according to reports by ABC News and legal filings cited by Premium Times.
The development underscores broader concerns about the safety of GLP-1 medications, which are primarily prescribed for type 2 diabetes and weight management. The US Food and Drug Administration (FDA) is currently reviewing potential safety signals connecting these drugs to NAION, following a 2024 study from a Boston health center that suggested a possible link between semaglutide—Ozempic and Wegovy’s active ingredient—and the condition. However, subsequent research has yielded mixed results, with no conclusive evidence establishing a direct causal relationship, as noted by ABC News.
Novo Nordisk, the producer of Ozempic and Wegovy, has dismissed the lawsuits as without merit, stating it takes adverse event reports seriously and continuously monitors the safety of its products. Eli Lilly, which manufactures Mounjaro and Zepbound, emphasized patient safety as its top priority, adding it evaluates all safety data, including potential eye-related side effects. Both companies have not acknowledged the specific allegations but reiterated their commitment to regulatory compliance.
The controversy has taken on new urgency in Nigeria, where GLP-1 drugs are increasingly accessible through social media and online vendors. A recent Premium Times investigation revealed that these prescription medications are being sold without medical supervision or prescriptions, with some vendors falsely claiming they have no side effects. The report also highlighted the circulation of retatrutide, an experimental drug still in clinical trials, further complicating the regulatory landscape.
NAFDAC, Nigeria’s regulatory body for pharmaceuticals, confirmed that medicines intended for commercial distribution must undergo registration before being marketed. However, the agency acknowledged that unregistered drugs may enter the market through
under specific conditions. NAFDAC had previously warned that Ozempic is not registered in Nigeria and that counterfeit versions of the drug are circulating, exacerbating public health risks.
The investigation found that vendors marketing GLP-1 injectables did not list their products on NAFDAC’s public registration database, raising questions about the authenticity and safety of the medications. Some vendors reportedly downplayed potential adverse effects, despite manufacturers’ warnings. This unregulated availability mirrors similar issues in the US, where legal actions have intensified scrutiny of the drugs’ safety profiles.
Al Jazeera reported that a US personal injury firm has filed over 90 lawsuits against Novo Nordisk in New Jersey state court since 2025, with additional cases in Pennsylvania. These legal challenges highlight the growing public and judicial attention on the potential risks of GLP-1 therapies, even as manufacturers maintain their stance on the drugs’ safety.
Ophthalmologists advising ABC News have urged individuals taking GLP-1 medications to seek immediate medical attention if they experience sudden, painless vision loss. The condition, while rare, underscores the importance of medical supervision and transparency in drug use, particularly in regions with weak regulatory enforcement.
The Nigerian context is further complicated by the lack of oversight in online pharmaceutical sales. Premium Times’ findings reveal that vendors openly market GLP-1 drugs on social media platforms, often bypassing traditional healthcare systems. This trend raises concerns about the long-term implications for public health, as unregulated access to prescription medications can lead to misuse and unmonitored side effects.
NAFDAC’s response to a Freedom of Information request emphasized that while registration is mandatory for commercial distribution, some unregistered medicines may enter the market through controlled pathways. However, the agency’s warnings about counterfeit Ozempic and the absence of verified listings for GLP-1 injectables highlight systemic gaps in regulatory enforcement.
The situation reflects a broader global debate over the balance between pharmaceutical innovation and patient safety. While GLP-1 drugs have shown efficacy in managing diabetes and obesity, their rapid adoption has outpaced comprehensive safety evaluations, particularly in regions with limited healthcare infrastructure.
Public health experts stress the need for stricter regulations and consumer education to mitigate risks associated with unapproved medications. In Nigeria, where access to healthcare remains uneven, the proliferation of unregulated GLP-1 drugs could exacerbate existing challenges, particularly for vulnerable populations.
The US lawsuits and Nigeria’s regulatory struggles illustrate the complexities of modern pharmaceutical markets. As demand for weight-loss and diabetes treatments grows, ensuring transparency and accountability in drug distribution becomes critical to protecting public health.
The case also underscores the importance of international collaboration in addressing drug safety. Regulatory bodies in the US, Europe, and Australia have flagged NAION as a rare but possible side effect of GLP-1 medications, yet enforcement remains inconsistent across jurisdictions.
For Nigerian patients, the situation serves as a cautionary tale about the risks of self-medication and the dangers of unregulated pharmaceutical markets. As GLP-1 drugs continue to gain popularity, stakeholders must prioritize safety, transparency, and equitable access to healthcare solutions.
The ongoing legal and regulatory developments in the US and Nigeria highlight the need for proactive measures to safeguard public health. With the potential for serious side effects and the risks of counterfeit drugs, ensuring that patients receive accurate information and proper medical guidance is essential for responsible drug use.